Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • CCCP (carbonyl cyanide m-chlorophenyl hydrazine): Mechani...

    2026-03-06

    CCCP (carbonyl cyanide m-chlorophenyl hydrazine): Mechanism, Evidence, and Limits in Mitochondrial Research

    Executive Summary: CCCP (carbonyl cyanide m-chlorophenyl hydrazine) is a potent chemical uncoupler of oxidative phosphorylation, collapsing the mitochondrial proton gradient and inhibiting ATP synthesis with high reproducibility in vitro (APExBIO). Its action as an anionic protonophore enables it to cross lipid bilayers and disrupt mitochondrial membrane potential, a property leveraged in disease modeling and biomarker discovery for disorders linked to mitochondrial dysfunction, such as Alzheimer’s disease (Yan et al., 2025). CCCP is insoluble in water but dissolves readily in DMSO and ethanol, with recommended usage restricted to research applications. No clinical or in vivo efficacy has been established, and its effects rely on specific biochemical and cellular contexts, requiring careful experimental controls. The product is available at high purity from APExBIO (SKU B5003), supporting standardized and reproducible workflows.

    Biological Rationale

    Mitochondria are the principal organelles for ATP production in eukaryotic cells. The process of oxidative phosphorylation depends on a proton gradient across the mitochondrial inner membrane. Disruption of this gradient is a hallmark of mitochondrial dysfunction, implicated in various neurodegenerative diseases, including Alzheimer’s disease (Yan et al., 2025). Experimental manipulation of the proton motive force enables researchers to probe disease mechanisms and assess mitochondrial resilience. CCCP (carbonyl cyanide m-chlorophenyl hydrazine) is widely utilized to model such dysfunction by inducing rapid, controlled collapse of the proton gradient. This approach allows for dynamic analysis of mitochondrial health, bioenergetic capacity, and downstream cellular effects. Human-derived cellular models, such as urine-derived stem cells, provide non-invasive platforms for these studies, facilitating translational research from bench to biomarker discovery.

    Mechanism of Action of CCCP (carbonyl cyanide m-chlorophenyl hydrazine)

    CCCP functions as an uncoupler of oxidative phosphorylation. Its molecular structure allows it to bind protons and traverse the mitochondrial inner membrane in a delocalized anionic state. CCCP shuttles protons across the lipid bilayer, collapsing the electrochemical gradient needed for ATP synthase activity (Yan et al., 2025). As a result, electron transport continues, but ATP production is blocked. In vitro, this leads to a rapid decrease in mitochondrial membrane potential (ΔΨm), measurable with potentiometric dyes. CCCP is insoluble in water but dissolves in DMSO (≥20.5 mg/mL) and ethanol (≥16.23 mg/mL), facilitating precise dosing. The compound is a yellow solid with high purity (∼98%) when supplied by APExBIO (SKU B5003) (APExBIO).

    Evidence & Benchmarks

    • CCCP induces rapid, dose-dependent loss of mitochondrial membrane potential in live cells, quantifiable within minutes via fluorescence microscopy (Yan et al., 2025).
    • CCCP exposure (1–10 μM, 37°C, standard culture media) results in mitochondrial hyperfission and fragmentation, as confirmed by AI-driven image analysis in urine-derived stem cells (Yan et al., 2025).
    • CCCP activates the λ phage lytic promoters (pL and pR) in E. coli K-12 in a RecA-dependent pathway, confirming its role as an energy poison in bacterial models (APExBIO).
    • CCCP-driven mitochondrial uncoupling is a standard for benchmarking new mitochondrial probes and disease models, with protocols standardized across multiple research labs (ApexPrep article).
    • No in vivo or clinical studies have demonstrated therapeutic benefit or safety of CCCP; its use is strictly limited to research (APExBIO).

    This article extends previous work (Defining the Gold-Standard Uncoupler) by integrating AI-powered imaging benchmarks and explicit disease modeling protocols, and clarifies distinctions from advanced mechanistic reviews (Mito-Scarlet), which focus on deeper molecular mechanisms. For workflow troubleshooting and vendor selection, see the scenario guide (ATP Solution), which this article updates with new purity and solubility data.

    Applications, Limits & Misconceptions

    CCCP is deployed to:

    • Model mitochondrial dysfunction in neurodegenerative, metabolic, and cancer immunotherapy research.
    • Benchmark mitochondrial probes and bioenergetic assays.
    • Induce viral gene expression via energy poisoning in bacterial models.
    • Enable AI-based phenotyping of mitochondrial morphology in live cell systems.

    However, CCCP cannot be used in vivo or in clinical studies. Its effects are context-dependent and reversible only at low doses and short exposure times. It is not a therapeutic agent, nor does it discriminate between healthy and diseased mitochondria.

    Common Pitfalls or Misconceptions

    • Assuming CCCP is safe or effective in animals or humans—no in vivo evidence supports this.
    • Overestimating specificity—CCCP uncouples all mitochondria, not just diseased populations.
    • Neglecting solubility—CCCP is insoluble in water; improper dissolution leads to inconsistent dosing.
    • Ignoring solution stability—CCCP solutions degrade with long-term storage; fresh preparation is essential.
    • Confusing mechanistic action—CCCP collapses the proton gradient but does not directly generate reactive oxygen species (ROS); ROS production is a downstream consequence dependent on cellular context.

    Workflow Integration & Parameters

    CCCP is best delivered in DMSO or ethanol, with final working concentrations between 1–10 μM, applied to cell cultures at 37°C in standard buffered media. For imaging or metabolic assays, exposure times typically range from 5–60 minutes depending on the endpoint. Solutions should be prepared fresh from powder stocks (≥98% purity, B5003) and used immediately (APExBIO). Controls must include vehicle only and, where relevant, alternative uncouplers for benchmarking. Downstream readouts include ΔΨm loss (fluorescent dyes), ATP depletion (luciferase/luminescence), and morphological changes (microscopy, AI segmentation). For best practices in troubleshooting and result interpretation, consult complementary workflow guides (ATP Solution).

    Conclusion & Outlook

    CCCP (carbonyl cyanide m-chlorophenyl hydrazine) remains the reference standard for controlled mitochondrial proton gradient disruption in vitro. As supplied by APExBIO (SKU B5003), it offers reproducible purity and solubility for advanced research. Its role as an energy poison has enabled breakthroughs in bioenergetics, biomarker development, and disease modeling, notably in the context of Alzheimer’s disease. However, its use is tightly constrained to laboratory settings, and all experimental designs must respect its solubility, stability, and non-clinical status. Future directions include coupling CCCP-induced stress with high-throughput AI analytics to refine early disease biomarkers and screen mitochondrial-targeted interventions. For the latest product specifications and validated protocols, see the CCCP (carbonyl cyanide m-chlorophenyl hydrazine) product page.